Higher mean platelet volume is accompanied with hyperthyroidism in patients with Graves’ disease
Abstract
Purpose: Graves’ disease (GD) is an autoimmune disease that is the most common cause of thyrotoxicosis. Thyrotoxicosis can cause a decrease in platelet survival time. Inflammation is an important stimulus for platelets and mean platelet volume (MPV) could be used a diagnostic marker which is an important determinant of platelet activity. In this study we aimed to evaluate whether MPV would be a useful inflammatory marker for evaluation of disease activity in patients with Graves’ disease.
Materials and Methods: Two hundred twenty-nine patients (GD patients (Group 1); n=102 and patients with euthyroid nodular goiter (Group 2); n= 127) were included in this retrospective study. Serum TSH, fT3, fT4 and MPV levels were recorded at presentation and at first euthyroid period under ATD treatment in GD patients and at presentation in patients with euthyroid nodular goiter.
Results: The mean age was 40.3±13.5 in Group 1 and 50.2±11.6 in Group 2. Mean initial MPV level did not differ between groups; 8.3±1.2 fL and 8.3±1.1 fL, respectively (p=0.9). We found that mean initial MPV was higher than the first euthyroid period MPV in Group 1; Graves’ group (8.3±1.2 fL vs 8.0±1.3 fL, p= 0.02). Conclusion: Higher initial MPV levels in Graves patients and significant drop following the restoration of hyperthyroidism may be due to hypermetabolism of hyperthyroidism.
Keywords
Kaynakça
- 1- Rosenbaum JT, Choi D, Wong A, Wilson DJ, Grossniklaus HE, Harrington CA et al. The Role of the Immune Response in the Pathogenesis of Thyroid Eye Disease: A Reassessment. PLoS One. 2015;15:10.
- 2- Penta L, Muzi G, Cofini M, Leonardi A, Lanciotti L, Esposito S. Corticosteroids in Moderate-To-Severe Graves’ Ophthalmopathy: Oral or Intravenous Therapy? Int. J. Environ. Res. Public Health. 2019;16:155.
- 3- Song RH, Qin Q, Wang X, Yan N, Meng S, Shi XH, et al. Differential cytokine expression detected by protein microarray screening in peripheral blood of patients with refractory Graves' disease. Clin Endocrinol (Oxf) 2015;84:402-7.
- 4- Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26:1343-1421.
- 5- Okada M, Kamiya Y, Ito J, Yoshimata T, Kawaguchı M, Shibata H, et al. Platelet Epidermal Growth Factor in Thyroid Disorders. Endocr J. 1998;45:83-8.
- 6- Panzer S, Haubenstock A, Minar E. Platelets in hyperthyroidism: studies on platelet counts, mean platelet volume, 111-indium-labeled platelet kinetics, and platelet-associated immunoglobulins G and M. J Clin Endocrinol Metab. 1990;70:491-96.
- 7- Erdogan Yucel E, Demiral Sezer S. Relationship Between the Neutrophil to Lymphocyte Ratio and the Presence and Size of Thyroid Nodules. Cureus. 2019;11:e3866.
- 8- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133.
- 9- Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J. 2017;6:225-37.
- 10- Park BJ, Shim JY, Lee HR, Jung DH, Lee JH, Lee YJ. The relation ship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: a focus on gender differences. Platelets. 2012;23:45–50.
